Enhanced recovery and early discharge of patients after septoplasty under sedation with dexmedetomidine

DOI: https://dx.doi.org/10.18565/pharmateca.2019.5.97-101

R.E. Leshchenko (1), N.S. Davydova (2)

1) Medical Association “New Hospital”, Yekaterinburg, Russia; 2) Ural State Medical University, Yekaterinburg, Russia

Background. Enhanced patient recovery after surgery and discharge on the day of hospitalization allows to avoid the development of a number of adverse events. Currently, there is no consensus on a sedative drug that can provide early discharge after septoplasty. In a clinical study, a comparative analysis of two groups of patients under sedation with dexmedetomidine and propofol was performed. Objective. Assessment of the possibility and determination of the causes of delay of enhanced recovery of patients after septoplasty under sedation with dexmedetomidine or propofol in the settings of multimodal anesthesia. Methods. A randomized, prospective study was conducted. Depending on the sedating medication used, the patients were divided into two groups: the group 1 (n=31) consisted of patients aged 35.09±11.13 years (M±δ) treated with septoplasty using propofol; the group 2 (n=30) – patients aged 38.83±11.32 years (M±δ) who underwent surgery under sedation with dexmedetomidine. Results. The duration of surgical intervention in the group 1 and group 2 was 58.35±16.43 and 41.13±16.25 minutes (M±δ), respectively. In both groups, the time to reach a score of 9–10 with the Aldrete scoring system was 0 minutes. In the group 1, two patients were discharged with a delay, in the group 2, all patients were discharged on the day of surgery. The clinically significant level of pain in the group 1 was the cause of delayed discharge. Conclusion. Sedation with dexmedetomidine in combination with multimodal anesthesia provides for discharge of patients on the day of septoplasty.

For citations: Leshchenko N.S., Davydova R.E. Enhanced recovery and early discharge of patients after septoplasty under sedation with dexmedetomidine. Farmateka. 2019;26(5):97–101. (in Russian). DOI: https://dx.doi.org/10.18565/pharmateca.2019.5.97-101 

About the Autors

Corresponding author: Roman E. Leshchenko, anesthesiologist-critical care physician, MA «New Hospital», Yekaterinburg, Russia; e-mal: leshenko.rel@yandex.ru; ORCID: https://orcid.org/0000-0002-1090-5132; Address: 55, Gurzufskaya Street, Yekaterinburg 620102, Russian Federation

Бионика Медиа